367 related articles for article (PubMed ID: 30509351)
1. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
Sim DS; Jeong MH; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY;
J Cardiol; 2019 Feb; 73(2):142-150. PubMed ID: 30509351
[TBL] [Abstract][Full Text] [Related]
2. Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting.
Sim DS; Jeong MH; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY;
J Cardiol; 2018 Nov; 72(5):411-419. PubMed ID: 29764713
[TBL] [Abstract][Full Text] [Related]
3. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
[TBL] [Abstract][Full Text] [Related]
6. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Gill K; Servati N; Flahive J; Fraielli K
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
[TBL] [Abstract][Full Text] [Related]
8. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
9. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
11. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.
De Luca L; Zeymer U; Claeys MJ; Dörler J; Erne P; Matter CM; Radovanovic D; Weidinger F; Lüscher TF; Jukema JW;
Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):94-103. PubMed ID: 31965164
[TBL] [Abstract][Full Text] [Related]
12. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
13. Precatheterization Use of P2Y
Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.
Park KH; Jeong MH; Kim HK; Ki YJ; Kim SS; Choi DH; Koh YY; Ahn Y; Kim HS; Gwon HC; Rha SW; Hwang JY;
J Korean Med Sci; 2021 Nov; 36(42):e268. PubMed ID: 34725976
[TBL] [Abstract][Full Text] [Related]
15. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
[TBL] [Abstract][Full Text] [Related]
16. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
17. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Venetsanos D; Träff E; Erlinge D; Hagström E; Nilsson J; Desta L; Lindahl B; Mellbin L; Omerovic E; Szummer KE; Zwackman S; Jernberg T; Alfredsson J
Heart; 2021 Jul; 107(14):1145-1151. PubMed ID: 33712510
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
[TBL] [Abstract][Full Text] [Related]
20. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
